cholesterol drug

Verve posts clean PCSK9 editor profile, teeing up Lilly decision

One year after axing an asset, the biotech has shown its Lilly-partnered successor can achieve similar LDL-C reductions without raising any red flags.

Nick Paul Taylor Apr 14, 2025 7:00am

heart cardiovascular check up stethescope

NewAmsterdam shares sign drug improves cardiovascular outcomes

Dec 10, 2024 8:48am

NewAmsterdam’s cholesterol ph. 3 hits, but disappoints investors

Nov 20, 2024 10:07am

YolTech sells China rights to gene editing therapy for $29M

Aug 27, 2024 10:24am

heart coronary artery cardiovascular scan MRI

Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol

May 29, 2024 11:00am

Verve shows base editing works in humans—and sees stock sink

Nov 13, 2023 8:43am